Seres Therapeutics grants 6,500 stock options to director

Seres Therapeutics, Inc. director Willard H. Dere received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share.

Rhea-AI Filing Summary

Seres Therapeutics, Inc. director Willard H. Dere received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, and expire on July 7, 2036. Following this award, Dere holds options for 6,500 shares directly.

Insights

Equity compensation analyst

Director received a routine stock option grant with time-based vesting.

Director Willard H. Dere was granted options on 6,500 shares of Seres Therapeutics common stock at an exercise price of $7.14 per share. This is compensation-related, not an open-market purchase or sale.

The options vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting after July 8, 2026, aligning Dere’s incentives with long-term performance and continued board service. The options expire on July 7, 2036, giving a long window to benefit from potential share price appreciation.

Insider Trade Summary

Grant/Award: 6,500 shares

Grant/Award 1 txn

Insider Dere Willard H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	6,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,500 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Key Figures

Option shares granted: 6,500 shares Exercise price: $7.14 per share Shares underlying options: 6,500 shares +2 more

5 metrics

Option shares granted 6,500 shares Stock Option (right to buy) granted to director Willard H. Dere

Exercise price $7.14 per share Conversion or exercise price of granted stock options

Shares underlying options 6,500 shares Underlying common stock for the stock option award

Post-grant derivative holdings 6,500 options Total options held following the reported transaction

Option expiration date July 7, 2036 Expiration date of the stock option award

Key Terms

Stock Option (right to buy), exercise price, vests and becomes exercisable, annual meeting of the Company's stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable on the earlier to occur"

annual meeting of the Company's stockholders regulatory

"the first annual meeting of the Company's stockholders occurring after July 8, 2026"

FAQ

What transaction did Seres Therapeutics (MCRB) report for director Willard H. Dere?

Seres Therapeutics reported that director Willard H. Dere received a grant of stock options covering 6,500 shares of common stock as equity compensation, rather than an open-market purchase or sale of existing shares.

How many Seres Therapeutics (MCRB) shares are covered by Dere’s new stock options?

The new stock option award to director Willard H. Dere covers 6,500 shares of Seres Therapeutics common stock. These options represent the right to buy that number of shares if the exercise conditions are met.

What is the exercise price of Willard H. Dere’s Seres Therapeutics (MCRB) stock options?

The stock options granted to Willard H. Dere have an exercise price of $7.14 per share. This is the price at which he may purchase Seres Therapeutics common stock once the options have vested and while they remain unexpired.

When do Willard H. Dere’s Seres Therapeutics (MCRB) stock options vest?

The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of Seres Therapeutics’ stockholders occurring after July 8, 2026, according to the filing footnote.

When do Willard H. Dere’s Seres Therapeutics (MCRB) stock options expire?

The stock options granted to Willard H. Dere expire on July 7, 2036. After that expiration date, any unexercised portion of the option award will no longer be exercisable for Seres Therapeutics common shares.

Is Dere’s Seres Therapeutics (MCRB) transaction a market buy or sell of shares?

No. The reported transaction is a grant of stock options, coded as an acquisition (A), not an open-market buy or sell of existing Seres Therapeutics shares. It reflects equity-based director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 04:15 PM Accepted by SEC EDGAR 07/10/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dere Willard H

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.14	07/08/2026		A		6,500		(1)	07/07/2036	Common Stock	6,500	$0	6,500	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

	/s/ Thomas J. DesRosier, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)